Publications by authors named "Prince S Gameli"

Article Synopsis
  • The synthesis and illegal use of designer benzodiazepines are increasing concerns, causing serious health risks and challenges for toxicologists in identifying and confirming their use.
  • The review analyzes the metabolism of various classes of benzodiazepines, highlighting key biomarkers for human consumption that are essential in toxicology.
  • A systematic literature search uncovered 30 studies on designer benzodiazepines' metabolism from 2007 to 2023, revealing prevalent metabolites and emphasizing the need for further research to address gaps in understanding these substances.
View Article and Find Full Text PDF

Background: The abuse of psychoactive substances presents challenges in clinical and forensic toxicology. The emergence of novel and potent drugs that pose significant health risks, in particular towards frequent abusers and users unaware of the ingredients, further complicates the situation. Designer benzodiazepines have become a fast-growing subgroup of these new psychoactive substances (NPSs), and their overdose may potentially turn fatal, especially when combined with other central nervous system depressants.

View Article and Find Full Text PDF

Ostarine (enobasarm) is a selective androgen receptor modulator with great therapeutic potential. However, it is also used by athletes to promote muscle growth and enhance performances without the typical adverse effects of anabolic steroids. Ostarine popularity increased in recent years, and it is currently the most abused "other anabolic agent" (subclass S1.

View Article and Find Full Text PDF

IOX2 is a potent inhibitor of prolyl hydroxylase 2, a key enzyme in the regulation of hypoxia-inducible factor (HIF) and oxygen homeostasis. As such, it can be used to enhance athletic performance and is currently banned by the World Anti-Doping Agency (WADA). Detection of metabolites is critical to demonstrate drug use in doping.

View Article and Find Full Text PDF

Anamorelin, developed for the treatment of cancer cachexia, is an orally active medication that improves appetite and food intake, thereby increasing body mass and physical functioning. It is classified as a growth hormone secretagogue and strictly monitored by the World Anti-Doping Agency (WADA), owing to its anabolic enhancing potential. Identifying anamorelin and/or metabolite biomarkers of consumption is critical in doping controls.

View Article and Find Full Text PDF